pyrroles has been researched along with Vascular Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, H; Jia, E; Wei, J; Xiao, M; Yan, G; Zhang, J | 1 |
| Apostolopoulos, V; Büsselberg, D; Caprnda, M; Hayes, A; Kruzliak, P; Matsoukas, J; Matsoukas, MT; Qaradakhi, T; Rimarova, K; Rybalka, E; Sepsi, M; Zulli, A | 1 |
| Bigham, Z; Damarla, M; Huetsch, J; Jiang, H; Kliment, C; Servinsky, L; Shimoda, LA; Suresh, K; Yun, X | 1 |
| Thibault, PK | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Abdalrahman, Z; Blanco, L; Brooks, SR; Furumoto, Y; Gadina, M; Hoffmann, V; Kaplan, MJ; Mast, L; Nunez, L; O'Shea, JJ; Remaley, AT; Sciumè, G; Smith, CK; Thacker, SG; Trier, AM; Tsai, WL; Zhao, W | 1 |
| Chae, JH; Choi, M; Choi, SA; Kang, JA; Kang, SJ; Kim, SY; Kim, Y; Kwon, SH; Lee, CR; Lee, DH; Lim, BC; Park, EB; Park, JD; Park, SG; Park, SH; Seo, J; Suh, DI; Ye, M | 1 |
| Daher, IN; Yeh, ET | 1 |
| Mikhailidis, DP; Paraskevas, KI; Veith, FJ | 1 |
| El-Bassossy, HM; El-Nagar, M; Mahmoud, MF | 1 |
| Ai, J; Ban, X; Niu, H; Sun, L; Wang, N; Xu, Y; Yang, B; Yu, Y; Zhang, R; Zhao, R | 1 |
| Lee, JD; Mikhailidis, DP; Morrissey, JR; Patel, V | 1 |
| Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B | 1 |
| Császár, A | 1 |
| Aznaouridis, K; Dagre, A; Masoura, C; Pitsavos, C; Skoumas, J; Stefanadi, E; Stefanadis, C; Vasiliadou, C; Vlachopoulos, C | 1 |
| Day, CA; Funovics, P; Heeba, G; Jacob, RF; Kubant, R; Malinski, T; Mason, RP; Medlin, YS | 1 |
4 review(s) available for pyrroles and Vascular Diseases
| Article | Year |
|---|---|
Neck vein obstruction: Diagnosis and the role of chronic persistent
Topics: Chlamydophila Infections; Chlamydophila pneumoniae; Chronic Disease; Humans; Neck; Pyrimidines; Pyrroles; Vascular Diseases | 2019 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Optimal statin type and dosage for vascular patients.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Tolerance; Endovascular Procedures; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Pyrroles; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Diseases; Vascular Surgical Procedures | 2011 |
[Vascular pleiosynergism--a new concept?].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Carrier Proteins; Cell Movement; Cell Proliferation; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Reactive Oxygen Species; Vascular Diseases | 2006 |
3 trial(s) available for pyrroles and Vascular Diseases
| Article | Year |
|---|---|
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases | 2014 |
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases | 2005 |
Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects.
Topics: Adult; Atorvastatin; Brachial Artery; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Oxidative Stress; Pyrroles; Salmonella typhi; Salmonella Vaccines; Systemic Inflammatory Response Syndrome; Vascular Diseases; Vasodilation | 2007 |
9 other study(ies) available for pyrroles and Vascular Diseases
| Article | Year |
|---|---|
Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib.
Topics: Humans; Livedo Reticularis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Diseases, Vascular; Skin Ulcer; Vascular Diseases | 2020 |
Alamandine reverses hyperhomocysteinemia-induced vascular dysfunction via PKA-dependent mechanisms.
Topics: Animals; Aorta, Abdominal; Carbazoles; Cyclic AMP-Dependent Protein Kinases; Hyperhomocysteinemia; In Vitro Techniques; Male; Molecular Docking Simulation; Oligopeptides; Protein Kinase Inhibitors; Pyrroles; Rabbits; Signal Transduction; Vascular Diseases | 2017 |
Reactive oxygen species induced Ca
Topics: Angiogenesis Inhibitors; Animals; Calcium; Cells, Cultured; Endothelium, Vascular; Hypertension, Pulmonary; Hypoxia; Indoles; Male; Microvessels; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; TRPV Cation Channels; Vascular Diseases | 2018 |
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Topics: Animals; Female; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Diseases | 2017 |
Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.
Topics: Child; Humans; Male; Membrane Proteins; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Diseases | 2017 |
Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Atorvastatin; Dietary Sucrose; Fructose; Heptanoic Acids; Insulin Resistance; Male; Pyrroles; Rats; Rats, Wistar; Vascular Diseases | 2012 |
Daming capsule restores endothelial dysfunction induced by high-fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Diet, High-Fat; Drugs, Chinese Herbal; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phytotherapy; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vascular Diseases; Vasoconstriction; Vasodilation | 2012 |
CARDS on the table: should everybody with type 2 diabetes take a statin?
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Vascular Diseases | 2005 |
Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.
Topics: Amlodipine; Atorvastatin; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Drug Synergism; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lipoproteins, LDL; Membrane Lipids; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Pyrroles; Vascular Diseases; X-Ray Diffraction | 2008 |